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Selective radiolabelling with 68Ga under mild conditions: a route 
towards a porphyrin PET/PDT theranostic agent 
Steven Y. Yap,a Thomas W. Price,b,c Huguette Savoie,a Ross W. Boylea* and Graeme J. Stasiukb,c*
A theranostic conjugate for use as a positron emission tomography 
(PET) radiotracer and as a photosensitiser for photodynamic 
therapy (PDT) has been synthesised. A water-soluble porphyrin was 
coupled with the bifunctional chelate, H4Dpaa.ga. This conjugate is 
capable of rapid 68Ga complexation under physiological conditions; 
with 93% and 80% radiochemical yields achieved, at pH 4.5 and pH 
7.4 respectively, in 15 mins at 25 °C. Photocytotoxicity was 
evaluated on HT-29 cells and showed the conjugate was capable of 
>50% cell death at 50 µM upon irradiation with light, while causing 
minimal toxicity in the absence of light (>95% cell survival).  
The goal of developing “personalised medicine” has seen a 
growing interest in the field of theranostics, a term often used 
for the combination of therapeutic and diagnostic modalities 
onto a single molecule. Current standardised cancer 
treatments, which have a “one-size-fits-all” methodology, often 
lead to significant difference in treatment outcomes.1 
Theranostics, however, allows the optimisation of treatment as 
it is capable of following the progression of disease before, 
during, and after treatment. 
Photodynamic therapy (PDT) is a minimally invasive 
treatment that involves the usage of a photosensitiser and 
molecular oxygen. An ideal photosensitiser will selectively 
accumulate in the diseased tissues after a given period, and 
upon irradiation with visible light (400 – 700 nm) the 
photosensitiser can generate highly toxic reactive oxygen 
species (ROS) which damage tissues in close proximity to the 
site of generation. Introducing a diagnostic modality to a PDT 
agent will allow careful monitoring of the degree of 
accumulation of photosensitiser, improving treatment 
outcomes by irradiation when photosensitiser levels are 
maximal. Porphyrins are chosen here as the photosensitiser 
because they offer: potent photocytotoxicity, minimal dark 
toxicity, ease of synthesis and functionalisation, and have 
selectivity for tumorous tissues.2–7  
Positron emission tomography (PET) is a highly sensitive 
medical imaging technique capable of functional imaging to 
observe metabolic changes in the human body. A wide variety 
of PET tracers have been developed,8 notable amongst these is 
[18F]-flurodeoxyglucose (FDG). FDG is widely used in cancer 
imaging.9 Incorporation of many PET isotopes (11C, 13N, 15O, 18F) 
requires the formation of covalent bonds in a rapid, specific 
manner following the production of the radioisotope in a 
cyclotron. This procedure must be performed rapidly to ensure 
delivery of a radiotracer with sufficient activity for imaging. This 
limits the application of PET using these tracers to sites with 
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Scheme 1 Synthesis of amine-appended porphyrin 5. (i) Propionic acid, 170 °C, 1 hr. (ii) 
EtOH/H2O, KOH, 40 °C, overnight. (iii) DMF, EDC, HOBt, DMAP, r.t., overnight. (iv) DMF, 
CH3I, 40 °C, overnight. (v) DCM, TFA, r.t., 3 hrs. 
Scheme 2 NHS esterification of H4Dpaa.ga. (i) MeCN, Ac2O, pyridine, r.t. 30 mins. (ii) DMF, 
NHS, TEA, r.t. 2 hrs.  
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ready access to cyclotron produced isotopes and specialised 
synthesis units. 
The use of 68Ga as a PET radioisotope has seen a significant 
growth in interest,10–12 culminating in the recent FDA approval 
of the [68Ga]-DOTATATE in July 2016.13 This interest is often 
attributed to development of the 68Ge/68Ga generator, allowing 
facile on-site generation of the desired radionuclide.11 68Ga can 
be readily incorporated into a radiotracer through the 
conjugation of a chelate to the targeting unit; this simplifies the 
synthesis that must be performed following production of the 
radionuclide. 
Porphyrins are known to be able to complex a host of 
metals.14 Not surprisingly, there are several reports showing the 
complexation of 68Ga by porphyrins as theranostic agents.15–19 
However, the complexation of 68Ga within the porphyrin core 
often requires harsh conditions; with reaction temperatures in 
excess of 100 °C are required. These conditions would be 
unsuitable for temperature-sensitive moieties, especially 
peptide-based targeting motifs and other biomolecules,12 and 
some porphyrins have been reported to degrade under these 
conditions.17 
Traditional macrocyclic chelators for 68Ga are 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 
1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA); however, 
these chelators also require harsh conditions for complexation 
which involves heating of over 80 °C (required for DOTA) and 
acidic conditions (pH 4).12 Recent developments in the design of 
chelates for 68Ga have resulted in a number of chelates that are 
capable of radiolabelling under less acidic conditions.20–22 
Herein we employ the use of a N,N-bis[(6-carboxypyridin-2-
yl)methyl]glutamic acid (H4Dpaa.ga, 6) bifunctional chelator, 
capable of rapidly chelating 68Ga at ambient temperature under 
physiological pH (pH 7.4) with excellent radiochemical yield 
(RCY).23 
We report here a water-soluble porphyrin-chelate 
conjugate, 9, that can be radiolabelled under neutral conditions 
without heating with good radiochemical yields. The resulting 
Ga(III) complex 10 displays good phototoxicity in HT-29 cells. 
Synthesis of an amine-appended porphyrin, 5, was 
achieved in 5 steps (Scheme 1) as previously reported. 24,25   
The porphyrin-chelate conjugate, 9, was prepared in a 3-
step process (Scheme 2) by activation of chelate 6, via an 
anhydride ring closing, and isolated by precipitation. This 
precipitate was used immediately to form the NHS ester, 8, by 
addition of N-hydroxysuccinimide. 8 was used without further 
purification.  
Addition of excess 8 to 5 yielded 9, (Scheme 3) with 
quantitative conversion of porphyrin 5 to conjugate 9 observed 
by TLC and HPLC. Purification was achieved using a simple 
technique previously reported by our group.25 The solubility of 
the porphyrin can be controlled by exchanging the anionic 
counter-ions. Exchange of the iodide anions with 
hexafluorophosphate rendered the conjugate insoluble in 
water. This allowed filtration and removal by washing of excess 
starting materials and reagents. Subsequent anionic conversion 
to chloride yielded the water-soluble conjugate 9. 
Scheme 3 Peptide coupling and gallium complexation of porphyrin-H3Dpaa conjugate. (i) DMF, TEA, r.t., overnight. (ii) 0.1 M pH 4.5 acetate buffer, GaCl3, r.t., overnight 
Figure 1 %cell survival of HT-29, irradiated cell and non-irradiated cells (control), 
determined using MTT assay. Cells were incubated with varying concentration of 10 for 
1 hour and irradiated cells received 20 J cm-1 white light.
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1H NMR spectroscopy indicated the characteristic 
aromatic signals of a porphyrin, methylated pyridinium protons, 
and pegylated protons from the linker. The spectrum also 
indicated picolinic acid protons and protons on the amino acid 
from H4Dpaa.ga both in the aromatic and in the alkyl regions. 
Analytical-HPLC also confirmed reaction (Figure S1 and Figure 
S2). 
Complexation with Ga(III)Cl3 was carried out under acidic 
conditions to produce the gallium complex, 10. Purification of 
the complex by exchanging the anionic counter-ions was 
successful in removing excess Ga(III). HPLC analysis confirmed 
the purity of the resulting complex (Figure S1). The identity of 
the product was confirmed by high resolution mass 
spectrometry; indicating the formation of a Ga(III) complex and 
the stability of the conjugate to the acidic conditions used.   
The photocytotoxicity of 9 and 10 was assessed in human 
adenocarcinoma (HT-29) cells (Figure 1, Figure S11). Cells were 
incubated with either 9 or 10 at varying concentrations and 
irradiation was carried using a constant dose of visible light (20 
J cm-2; 400 – 700 nm). The results were compared to a non-
irradiated control. Although in a clinical setting, red light is more 
commonly used for PDT, the strength and power of clinical 
lasers used in PDT are significantly more powerful compared to 
the quartz tungsten halogen light source used in this study. 
Hence, to compensate for the lower power, white light was 
used, covering the whole porphyrin absorbance range, 
including the strong Soret band at 424 nm (Figure S10). 
Under these conditions, >50% cell death was observed at 
50 µM, and >90% cell death was observed at a concentration of 
160 µM for both 9 and 10 when irradiated. Minimal dark toxicity 
was observed in the non-irradiated controls with more than 
95% cell survival at all concentrations tested (Figure 1). This 
shows phototoxicity at a similar concentration to a clinically 
relevant porphyrin PDT agent, Photofrin®, in HT-29 cells.26  
The radiolabelling efficiency of the conjugate 9 with 68Ga 
to form [68Ga]-10 was assessed at two different pHs - pH 4.5 and 
pH 7.4. At pH 4.5 and 25 °C, 6 and 9 complexed 68Ga with RCY of 
>99% (Figure S3) and 93% (Figure 2) respectively in 15 minutes. 
At pH 7.4 and 25 °C, 6 and 9 complexed 68Ga with RCY of 96% 
(Figure S3) and 80% (Figure 2) respectively in 15 minutes. 
Radiolabelling of 5 was also attempted with 68Ga, with 
conventional heating at 99 °C. At both pH 4.5 and pH 7.4, no 
radiolabelling was observed (Figure S3). This shows that, even 
with heating, the porphyrin moiety did not take part in gallium 
complexation.  
  The novel agent, [68Ga]-10, demonstrates a strategy to 
produce porphyrin PDT agents that can be selectively and 
readily radiolabelled under mild conditions with 68Ga for PET. 
Phototoxicity and toxicity of 9 and 10 was evaluated on human 
adenocarcinoma (HT-29) cells with and without irradiation with 
visible light respectively. Neither system showed significant 
toxicity in the absence of irradiation and both were capable of 
inducing cell death when irradiated. The conjugate 9 is capable 
of 68Ga complexation at physiological conditions (15 minutes, 
pH 7.4, room temperature) to produce [68Ga]-10 with a RCY of 
80%, thus providing a route towards a 68Ga labelled porphyrin 
PET/PDT theranostic agent. 
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